Chemistry and Cancer
Discovering drug-like chemicals that affect biological processes related to the development or inhibition of cancer
The Chemistry and Cancer Scientific Program focuses on discovery of small molecule agonists/antagonists of regulatory pathways relevant to human cancer. In a chemistry-to-biology direction, novel cytotoxic natural products and total synthetic derivatives are subjected to biochemical, genetic, or molecular biological studies aimed at resolving their precise mode-of-action.
Alternatively, attempts to identify small molecule agonists/antagonists of regulatory pathways relevant to cancer will be prosecuted via high throughput drug screening, medicinal chemistry, peptidomimetics, or synthetic analogs of biologic metabolites.
For more information, contact:
- Steven McKnight, Ph.D.
firstname.lastname@example.org" style="font-size: 12.00119972229px; line-height: 1.5;
- Jef De Brabander, Ph.D.
- Identifying the molecular targets of cancer cell–specific small-molecule toxins
- Biochemical dissection of novel, cancer cell–specific pathways
- Proof-of-concept preclinical development of cancer cell–specific small-molecule toxins
- Dissection, regulation, and targeting of the hypoxia response pathway
How To Get Involved
The Chemistry and Cancer Scientific Program seeks additional physicians and scientists having both broader and deeper understanding of human cancer to further collaboration of new scientific directions for HTS assays, peptidomimetic projects, and new natural product opportunities.
Program meetings every other Friday morning are attended by all investigators, postdoctoral fellows, students, and scientist-level technical staff.